Merck (MRK) is among those interested in Inhibrx's (INBX) experimental cancer drug, Reuters reports citing source

This development indicates that Merck's interest in Inhibrx's experimental cancer drug could lead to potential strategic collaboration or acquisition, which may enhance Merck's oncology portfolio.

Newsquawk StaffPublished On the live feed at 5 more headlines followed before this page went public
Newsquawk headlinesUTC

EU's EUR 90bln Ukraine loan to move ahead after Hungary lifts block, according to Bloomberg

Best Buy (BBY) says Jason Bonfig is to succeed Corie Barry as CEO

Merck (MRK) is among those interested in Inhibrx's (INBX) experimental cancer drug, Reuters reports citing source

Turkish CBRT Policy Announcement (Apr) 37% (exp. 37%, prev. 37%)

Moody's (MCO) Q1 2026 (USD): EPS 4.33 (exp. 4.24), Revenue 2.08bln (exp. 2.07bln)

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

Such moves can signal confidence in Inhibrx's technology and could impact valuations for both companies, as well as spark interest across the pharmaceutical sector in related assets.

Related headlines

The whole workspace, free to try.

Try it free